These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17971813)

  • 21. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research and development strategies, examples among new vaccines].
    Denis F; Ploy MC
    Ann Pharm Fr; 2009 May; 67(3):198-202. PubMed ID: 19446670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New vaccine approaches for seasonal and pandemic influenza.
    Palache B
    Vaccine; 2008 Nov; 26(49):6232-6. PubMed ID: 18674583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress with human H5N1 vaccines: a perspective from industry.
    Palache B; Krause R
    Expert Rev Vaccines; 2009 Apr; 8(4):391-400. PubMed ID: 19348556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on influenza A (H1N1) 2009 monovalent vaccines.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Oct; 58(39):1100-1. PubMed ID: 19816398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of MDCK cells for production of live attenuated influenza vaccine.
    Liu J; Shi X; Schwartz R; Kemble G
    Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
    Barrett PN; Mundt W; Kistner O; Howard MK
    Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The application and research advances of Brucella vaccines].
    Ding JB; Mao KR; Cheng JS; Dai ZH; Jiang YW
    Wei Sheng Wu Xue Bao; 2006 Oct; 46(5):856-9. PubMed ID: 17172046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic characterization and protective immunity of cold-adapted attenuated avian H9N2 influenza vaccine.
    Lee JS; Kim HS; Seo SH
    Vaccine; 2008 Dec; 26(51):6569-76. PubMed ID: 18838096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuated influenza A viruses with modified cleavage sites in hemagglutinin as live vaccines.
    Stech J
    Expert Rev Vaccines; 2008 Aug; 7(6):739-43. PubMed ID: 18665773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.
    Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL
    Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.
    Wressnigg N; Voss D; Wolff T; Romanova J; Ruthsatz T; Mayerhofer I; Reiter M; Nakowitsch S; Humer J; Morokutti A; Muster T; Egorov A; Kittel C
    Vaccine; 2009 May; 27(21):2851-7. PubMed ID: 19366569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent trends in the developments of bacterial vaccines.
    Lindberg AA; Pillai S
    Dev Biol Stand; 1996; 87():59-71. PubMed ID: 8854003
    [No Abstract]   [Full Text] [Related]  

  • 39. Current developments in avian influenza vaccines, including safety of vaccinated birds as food.
    Swayne DE; Suarez DL
    Dev Biol (Basel); 2007; 130():123-33. PubMed ID: 18411943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?
    O'Hagan DT; Wack A; Podda A
    Clin Pharmacol Ther; 2007 Dec; 82(6):740-4. PubMed ID: 17971820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.